High throughput screening of active pharmaceutical ingredients by UPLC.
Ultra performance LC (UPLC) was evaluated as an efficient screening approach to facilitate method development for drug candidates. Three stationary phases were screened: C-18, phenyl, and Shield RP 18 with column dimensions of 150 mm x 2.1 mm, 1.7 microm, which should theoretically generate 35,000 plates or 175% of the typical column plate count of a conventional 250 mm x 4.6 mm, 5 microm particle column. Thirteen different active pharmaceutical ingredients (APIs) were screened using this column set with a standardized mobile-phase gradient. The UPLC method selectivity results were compared to those obtained for these compounds via methods developed through laborious trial and error screening experiments using numerous conventional HPLC mobile and stationary phases. Peak capacity was compared for columns packed with 5 microm particles and columns packed with 1.7 microm particles. The impurities screened by UPLC were confirmed by LC/MS. The results demonstrate that simple, high efficiency UPLC gradients are a feasible and productive alternative to more conventional multiparametric chromatographic screening approaches for many compounds in the early stages of drug development.
Merck & Co. Inc., Rahway, NJ 07065, USA. mohammed_al-sayah@merck.com
Mohammad A
MA
Al-Sayah
Panagiota
P
Rizos
Vincent
V
Antonucci
Naijun
N
Wu
D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods*; D002853:Chromatography, Liquid; D004340:Drug Contamination; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D013058:Mass Spectrometry; D004364:Pharmaceutical Preparations / Q000302:isolation & purification*
D004364:Pharmaceutical Preparations